AmpliPhi Biosciences Nets $9.1M From IPO

San Diego-based AmpliPhy Biosciences, a developer of therapies for treating drug-resistant bacterial infections using bacteriophage technology, said it raised $9.1M for the company in its IPO. The company trades as APHB on the NYSE Small Cap Market. The $9.1M was after deducting the underwriting discount and commissions and estimated offering expenses payable by AmpliPhi, according to the company. The company's IPO offering was run by Rodman & Renshaw.